Poly Medicure Limited — PPTs, 07-03-2026: Investor Presentation

Poly Medicure posted solid 9M FY26 consolidated revenue of Rs 1340.7 Cr, up 9.1% year-on-year, with net profit rising 3.6% to Rs 255.7 Cr. Domestic sales were a key driver, surging 17.6%, while international growth also contributed. Infusion Therapy remains the largest segment, making up 60% of revenue.

The company is strategically advancing into higher-technology medical devices through acquisitions like Pendracare (Cardiology) and Citieffe (Orthopaedics). Domestically, the focus is on import substitution, launching 25-30 new products annually, and expanding its sales footprint with over 100 new hires in FY27.

Recent developments include a second Haridwar plant becoming operational and a new gamma sterilization facility. Poly Medicure is also set to launch new products in Cardiology (IVL, DEB), Critical Care, and Pediatrics, with Orthopaedics plates planned by FY28.

Management plans to double R&D spend, with over 100 products in the pipeline for the next 3-4 years, and further capacity expansion with a Palwal plant by FY27. They are actively pursuing global expansion for their cardio portfolio and deepening market penetration.